168 related articles for article (PubMed ID: 38730464)
1. Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer.
Qin W; Li J; Gao N; Kong X; Guo L; Chen Y; Huang L; Chen X; Qi F
Mol Cancer; 2024 May; 23(1):99. PubMed ID: 38730464
[TBL] [Abstract][Full Text] [Related]
2. Multi-omics analysis elucidates the relationship between intratumor microbiome and host immune heterogeneity in breast cancer.
Li J; Zhang Y; Cai Y; Yao P; Jia Y; Wei X; Du C; Zhang S
Microbiol Spectr; 2024 Apr; 12(4):e0410423. PubMed ID: 38442004
[TBL] [Abstract][Full Text] [Related]
3. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
5. Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients.
Mu G; Ji H; He H; Wang H
Breast Cancer; 2021 Mar; 28(2):513-526. PubMed ID: 33245478
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
[TBL] [Abstract][Full Text] [Related]
7. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
Huang J; Zhang JL; Ang L; Li MC; Zhao M; Wang Y; Wu Q
Front Endocrinol (Lausanne); 2023; 14():1265520. PubMed ID: 37900131
[TBL] [Abstract][Full Text] [Related]
8. Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.
Chen L; Jenjaroenpun P; Pillai AM; Ivshina AV; Ow GS; Efthimios M; Zhiqun T; Tan TZ; Lee SC; Rogers K; Ward JM; Mori S; Adams DJ; Jenkins NA; Copeland NG; Ban KH; Kuznetsov VA; Thiery JP
Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2215-E2224. PubMed ID: 28251929
[TBL] [Abstract][Full Text] [Related]
9. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway.
Fang K; Hu C; Zhang X; Hou Y; Gao D; Guo Z; Li L
Carcinogenesis; 2020 Sep; 41(9):1273-1281. PubMed ID: 31784750
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement.
Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G
Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306
[TBL] [Abstract][Full Text] [Related]
11. Untangling determinants of gut microbiota and tumor immunologic status through a multi-omics approach in colorectal cancer.
Zhang SL; Cheng LS; Zhang ZY; Sun HT; Li JJ
Pharmacol Res; 2023 Feb; 188():106633. PubMed ID: 36574857
[TBL] [Abstract][Full Text] [Related]
12. Integrated multiomics analyses unveil the implication of a costimulatory molecule score on tumor aggressiveness and immune evasion in breast cancer: A large-scale study through over 8,000 patients.
Zhang D; Wang Y; Zhao F; Yang Q
Comput Biol Med; 2023 Jun; 159():106866. PubMed ID: 37068318
[TBL] [Abstract][Full Text] [Related]
13. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
14. An unexpected link: The role of mammary and gut microbiota on breast cancer development and management (Review).
Toumazi D; El Daccache S; Constantinou C
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786630
[TBL] [Abstract][Full Text] [Related]
15. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
[TBL] [Abstract][Full Text] [Related]
16. Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator-activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue.
Wilson HE; Rhodes KK; Rodriguez D; Chahal I; Stanton DA; Bohlen J; Davis M; Infante AM; Hazard-Jenkins H; Klinke DJ; Pugacheva EN; Pistilli EE
Clin Cancer Res; 2019 Apr; 25(7):2336-2347. PubMed ID: 30559167
[TBL] [Abstract][Full Text] [Related]
17. Low serum gastrin associated with ER
Meng LL; Wang JL; Xu SP; Zu LD; Yan ZW; Zhang JB; Han YQ; Fu GH
BMC Cancer; 2018 Aug; 18(1):824. PubMed ID: 30115027
[TBL] [Abstract][Full Text] [Related]
18. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.
Wu Y; Zhang Y; Zhang W; Huang Y; Lu X; Shang L; Zhou Z; Chen X; Li S; Cheng S; Song Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12513-12534. PubMed ID: 37382675
[TBL] [Abstract][Full Text] [Related]
19. Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer.
Zou S; Yang C; Zhang J; Zhong D; Meng M; Zhang L; Chen H; Fang L
J Transl Med; 2024 Feb; 22(1):175. PubMed ID: 38369542
[TBL] [Abstract][Full Text] [Related]
20. Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression.
Huang Z; Li X; Xie T; Gu C; Ni K; Yin Q; Cao X; Zhang C
Cancer Res Treat; 2020 Oct; 52(4):1067-1083. PubMed ID: 32599985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
